- Pientzehuang Pharma reported a net income of 1.44 billion yuan for the first half of the year.
- The company’s total revenue for this period was 5.38 billion yuan.
- Current market recommendations include 14 buy ratings, 1 hold rating, and 2 sell ratings.
A look at Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
With a solid overall outlook, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. seems to have promising long-term prospects. The company scores well in Dividend, Growth, and Resilience, indicating a strong foundation for future success. Known for manufacturing and marketing Chinese traditional medicines such as Pientzehuang and related products like capsules and cough syrup, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. shows resilience and growth potential within the pharmaceutical industry.
While the Value and Momentum scores are not as high, the company’s strengths in Dividend, Growth, and Resilience suggest stability and potential for expansion. Investors may find Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. an attractive option for long-term investment based on its positive performance across key factors.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
